Dear Members,

Your Directors are pleased to present the thirty-seventh Annual Report and the audited financial statements for the financial year ended March 31,2025.

FINANCIAL RESULTS

(' in Crores)

RESULTS OF OPERATIONS

During the year under review, the income from operations of the Company grew by 9% to ' 1,356.36 Crores against ' 1,244.70 Crores in the previous year.

The profit before tax increased by 30% to ' 216.32 Crores as compared to ' 166.11 Crores in the previous year. The profit after tax also increased by 30% to ' 160.99 Crores as compared to ' 123.96 Crores in the previous year.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE COMPANY

No material changes and commitment affecting the financial position of the Company, has occurred between the financial year ended on March 31,2025, and the date of the report. There has been no change in the nature of business of the Company.

DIVIDEND

The Board of Directors have recommended a dividend of ' 4.50 per equity share (45% on face value of ' 10 per share) on the paid-up equity share capital of the Company for the financial year ended March 31, 2025, amounting to ' 41.25 Crores, which if approved, at the forthcoming Annual General Meeting on September 24, 2025, will be paid on or after September 28, 2025, to the Members whose names appear in the Register of Members, as on September 18, 2025, being the record date fixed for this purpose. In respect of shares held in electronic form, the dividend will be paid on the basis of beneficial ownership furnished by the depositories viz., NSDL and CDSL for this purpose.

The dividend recommended is in accordance with the Company's Dividend Distribution Policy.

I n view of the changes made under the Income-tax Act, 1961, by the Finance Act, 2020, dividends paid or distributed by the Company shall be taxable in the hands of the shareholders. Your Company shall, accordingly, make the payment of the dividend after deduction of tax at source.

DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI Listing Regulations], the Board of Directors of the Company had formulated a Dividend Distribution Policy ('the Policy'). The Policy is available on the Company's website at . Policy.pdf .

TRANSFER TO RESERVES

The Company does not propose to transfer any amount to general reserve on declaration of dividend. The Board of Directors have decided to retain the entire amount of profits for FY 2024-2025 in the distributable retained earnings.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The Company has no subsidiaries or associate companies. Also, it does not have any joint venture operation with any other entity.

THE STATE OF COMPANY AFFAIRS

The Hospital remained committed to providing world class quality healthcare and services. Focus continued on improving operational efficiencies across functions, improving patient services and enhancing safety for patients and staff.

During the year under review, several complex procedures were performed by our team of clinicians, bringing respite to many chronically ill patients and their families. The following rare procedures were performed at the Indraprastha Apollo Hospital:

?€? First robotic left lateral donor hepatectomy was performed for a one-year-old child with biliary atresia, with his father as the donor. Despite the complex anatomy, the surgery went smoothly. The donor was discharged on the sixth day, and the recipient was discharged two and a half weeks post-transplant.

?€? A 16-year-old boy from Egypt with dilated cardiomyopathy (DCMP) and end-stage heart failure urgently needed a heart transplant but was too ill to wait for a matching donor heart. In the year 2021, he was implanted with a Heart Mate 3 LVAD and recovered well. Since then, he had been on the waiting list for a donor heart. During the year under review, matched donor heart was found. The heart was retrieved and he successfully underwent a Heart Transplant. His recovery was smooth, and he was discharged after eleven days. He continues to be on follow up with us. This marks the 5th Heart Transplant at Indraprastha Apollo Hospitals.

?€? A 31-year-old female from Kenya presented with occasional back pain and abdominal pain. She was diagnosed with Takayasu's arteritis thoracoabdominal aortic aneurysm (TAAA) and anti-nuclear antibodies (ANA) positive. She was on immunosuppressants and anticoagulation posing a significant challenge to the treatment. After multi-disciplinary optimisation, she underwent open repair of the TAAA. Her postoperative period was complex but eventually patient made a complete recovery and discharged after 10 days.

?€? A 46-year-old female was diagnosed with left eye Choroidal Melanoma after experiencing flashes of light and photopsia for two months. Fundoscopy and CE-MRI of the orbit confirmed a choroidal melanoma extending near the optic nerve without completely covering it. For the first time, we successfully performed GRS with ZAP-X on a patient with ocular melanoma, delivering a precise dose to the lesion under anesthetic sedation. The procedure was well tolerated, and at the 1.5-month follow-up, the patient's vision remains intact, and she continues to do well.

?€? A 69-year-old male, presented with persistent uncontrolled Hypertension on 4 Anti-hypertensive drugs with Left Ventricular Failure. Patient had significant coronary artery disease- status post PTCA stent and Cerebrovascular Disease- Old Stroke, Status post Carotid Artery Stenting and Vertebral Artery stenting. He underwent Percutaneous sympathetic Renal Denervation Therapy which successfully reduced his Blood Pressure.

?€? A Computer-Assisted Reverse Shoulder Replacement was successfully performed on a 67-year-old patient suffering from chronic shoulder pain due to advanced degenerative arthritis. The procedure utilised cutting- edge 3D preoperative planning software, which enabled precise implant positioning, enhanced surgical accuracy, and is expected to significantly improve the long-term function and durability of the prosthetic joint.

?€? A 22-year-old MBBS student, battling unexplained transient ischemic attacks for years, faced a sudden stroke. An extensive neurological and vascular workup revealed -multiple pulmonary arteriovenous malformations (PAVMs), two of which were critical, a rare but dangerous condition allowing paradoxical embolism. Using vascular plugs and coils, the largest AVMs were embolised, successfully closing the shunt and preventing further embolisation. Oxygen saturation surged from critically low levels of 75% to 96%, cyanosis resolved, and clubbing regressed.

Apollo Hospital, Noida continued to perform well across all operational parameters and remained one of the leading destinations for Mother and Child Care, Minimal Invasive Laparoscopic Surgeries, Dialysis & Daycare Chemotherapy and Preventive Health Checks.

On a Public Interest Litigation (PIL) regarding free treatment in the hospital, the Hon'ble Delhi High Court vide its order dated September 22, 2009, has held that free treatment provided by the hospital shall be inclusive of medicines & medical consumables.

The Company has filed a Special Leave Petition (SLP) before the Hon'ble Supreme Court of India challenging the order of the Hon'ble Delhi High Court. The Hon'ble Supreme Court has admitted the SLP and has passed an interim order on November 30, 2009, pursuant to which, the Company has been providing free treatment to the patients referred by the Government of NCT of Delhi and has been charging only for

medicines & medical consumables. The financial impact in the matter can be quantified only after the final decision by the Hon'ble Supreme Court of India.

The Directorate of Health Services, Government of NCT of Delhi, has appointed a Nodal Medical Officer to be permanently stationed in the Hospital to support, guide and monitor the treatment of patients referred by the Government.

The Company has moved an Interlocutory Application before the Hon'ble Supreme Court seeking direction that the conditions relating to provision of free treatment facilities for patients belonging to indigent category to the extent of 10% IPD and 25% OPD be made applicable to the Company as have been made applicable in case of other hospitals. Additionally, the Company has also made representations before the Government of NCT of Delhi to allow the Company to extend free treatment including medicines and consumables up to 10% IPD and 25% OPD as applicable to other hospitals.

During the year, a total of 45,133 patients (40,378 Out Patients and 4,755 In Patients) were treated under the free category.

Awards and Accolades

The Hospital received a number of awards and accolades during the year. Some of them are as under: -

?€? Best Private Multispecialty Hospital in Delhi by The Week - Hansa Research Survey.

?€? Sanjeevani 2024 healthcare and wellness Expo Certificate of recognition in Pediatric hematology & bone marrow transplant, Kidney transplant and Radiation oncology.

?€? World's best hospital by Newsweek.

?€? Excellence in clinical services by Association of Healthcare Providers of India (AHPI).

?€? National winner sustainability award by CAHOCON.

?€? Best hospital in Neurology & Neurosurgery and Oncology radiation by Medical Value Travel Award

?€? Codestemi-clinical effectiveness - Hospital Management Asia.

?€? JCI Prime Certification.

Accreditation

Healthcare accreditation is one of the major steps towards improving quality and patient safety. Indraprastha Apollo Hospitals was the first hospital in the country to get Joint Commission International (JCI) accreditation in the year 2005. It has been reaccredited for the seventh time in December, 2023.This milestone is a testament to our commitment to maintaining the highest standards of patient care and safety.

CORPORATE GOVERNANCE

The Company is committed to maintain the highest standards of corporate governance and adhere to the corporate governance requirements set out by SEBI. The report on corporate governance as required under the Listing Regulations, forms an integral part of this report. The requisite certificate from Mr. Baldev Singh Kashtwal, Practicing Company Secretary, confirming the compliance with the conditions of corporate governance is attached to the report on Corporate Governance.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis Report for the year under review, as stipulated under Listing Regulations, forms an integral part of this report.

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT

In terms of the provisions of the Listing Regulations, the Business Responsibility & Sustainability Report is not appliable to Company.

SEXUAL HARASSMENT POLICY

The Company has adopted a policy on prevention, prohibition and redressal of sexual harassment at the workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed thereunder. The Company has an Internal Complaints Committee (ICC) for providing a redressal mechanism pertaining to sexual harassment of women employees at the work place.

The following is a summary of sexual harassment complaints received and disposed off during the year:

*In 3 complaints, enquiry by the ICC had not concluded at the end of the financial year.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Company has established a vigil mechanism for Directors and Employees to report their genuine concerns, the details of which are given in the Corporate Governance Report. The Whistle Blower Policy may be accessed on com/delhi/2024/Whistle-Blower-Policy.pdf During the year, no matter or incident has been received under the Whistle Blower Policy of the Company.

PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED

During the year, the Company has not given any loan or made an investment, nor given any guarantee in terms of Section 186 of the Companies Act, 2013.

DEPOSITS

During the year, the Company has not accepted any deposit as contemplated under Chapter V of the Companies Act, 2013.

DIRECTORS AND KEY MANAGERIAL PERSONNEL Board Composition and Independent Directors

As at the end of the day on 31st March 2025, the Board consisted of four Non-Executive - Non-Independent Director, one Executive Director and six Independent Directors.

Independent directors are appointed, based on the recommendation of the Nomination and Remuneration Committee, for a term of five years and are not liable to retire by rotation. In the opinion of the Board, the Independent Directors fulfil the conditions specified in the Listing Regulations and are independent of the management.

All Independent Directors have given their declarations that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation 16(b) of the SEBI Listing Regulations.

In the opinion of the Board, the Independent Directors possess the requisite expertise and experience and are persons of high integrity and repute. They fulfill the conditions specified in the Act and the Listing Regulations and they are independent of the management.

Retirement by Rotation

Pursuant to Section 152 of the Companies Act 2013, Dr. Suneeta Reddy and Dr. Sangita Reddy, Directors, retire by rotation at the ensuing Annual General Meeting and being eligible, have offered themselves for re-appointment. Based on the outcome of the performance evaluation process, the Board recommends their reappointment. The notice convening the AGM, to be held on September 24, 2025, sets out the relevant details.

Change in Board Composition

Mr. Sandip Somany (DIN 00053597) and Mr. Tejpreet Singh Chopra (DIN 00317683) have been appointed as Independent Directors of the Company, for a period of 5 consecutive years effective from April 1,2024 to March 31, 2029.

Dr. Menaka Guruswamy (DIN 08742679) completed her tenure viz. first term of five (5) consecutive years on May 22, 2025, as Independent Director on the Board of Directors of the Company. Owing to her professional commitments and law practice as a Senior Advocate at the Supreme Court of India, she opted not to renew her second term as an Independent Director on the Board of Directors of the Company. Consequently, she ceased to be the Independent Director of the Company.

Dr. Arun Rai (DIN 07159822) completed his tenure viz. second term of five (5) consecutive years on May 25, 2025, as Independent Director on the Board of Directors of the Company. Consequently, he ceased to be the Director of the Company.

Mr. Sudhir Jalan (DIN 00111118) has been appointed as Independent Director of the Company, for a period of 5 consecutive years effective from August 6, 2025 to August 5, 2030.

The Company is yet to get nomination from the Govt. of NCT of Delhi for appointment of 3 Directors including Chairman of the Company.

The Board places on record its appreciation for the invaluable contribution and guidance given by Dr. Arun Rai and Dr. Menaka Guruswamy as Independent Director of the Company.

Key Managerial Personnel

Pursuant to the provisions of Section 203 of the Companies Act, 2013, the Key Managerial Personnel of the Company are Mr. Shivakumar Pattabhiraman - Managing Director, Mr. C. P. Tyagi - Chief Financial Officer and Mr. Priya Ranjan - Associate Vice President - Corporate Affairs & Legal.

Board Evaluation

Pursuant to the provisions of the Companies Act, 2013, and in terms of Regulation 17(10) of the SEBI Listing Regulations, the Board has carried out an annual performance evaluation of its own performance, the Directors individually as well as the working of the Committees. The manner in which the evaluation has been carried out has been enumerated in the Corporate Governance Report.

NOMINATION & REMUNERATION POLICY

The Board has, on the recommendation of the Nomination and Remuneration Committee, approved a policy for selection and appointment of Directors, Senior Management team and their remuneration. Note on the Remuneration Policy is mentioned in the Corporate Governance Report.

MEETINGS OF THE BOARD

The Board met five times during the financial year, the details of which are given in the Corporate Governance Report. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013, read with the Listing Regulations.

RISK MANAGEMENT

The Board of Directors has constituted a Risk Management Committee to identify elements of risk in different areas of operations and to develop a policy for actions associated to mitigate the risks. The Committee on a timely basis informed the members of the Board about risk assessment and minimisation procedures. In the opinion of the Committee, there was no risk that may threaten the existence of the Company. The details of the Risk Management Committee are included in the Corporate Governance Report.

INTERNAL FINANCIAL CONTROLS AND THEIR ADEQUACY

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations.

The Internal Audit function reports to the Audit Committee to maintain its objectivity and independence. Details of the internal control system and its terms of reference are set out in the Management Discussion and Analysis Report forming part of the Board's Report.

The Board of Directors has laid down internal financial controls to be followed by the Company and the policies and procedures to be adopted by the Company for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information. The Audit Committee evaluates the internal financial control systems periodically.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant material orders passed by the Regulators / Courts which would impact the going concern status of the Company and its future operations.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act 2013, the Board of Directors, to the best of their knowledge, hereby state and confirm:

a. that in the preparation of the annual financial statements for the year ended March 31, 2025, the applicable accounting standards have been followed along with proper explanations relating

to material departures, if any;

b. that such accounting policies have been selected and applied consistently, and judgement and estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31,2025, and of the profit of the Company for the year ended on that date;

c. that proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 201 3, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. that the annual financial statements have been prepared on a going concern basis;

e. that proper internal financial controls were in place and that the financial controls were adequate and were operating effectively;

f. that systems to ensure compliance with the provisions of all applicable laws were in place and were adequate and operating effectively.

SHARE CAPITAL

The paid-up Equity Share Capital as on March 31, 2025, was ' 91.67 Crores.

During the year under review, the Company has not issued shares with differential voting rights nor granted stock options nor sweat equity. As of March 31,2025, the details of shareholding in the Company held by the Directors are set out in the Corporate Governance Report forming part of the Board's Report.

EMPLOYEE STOCK OPTIONS

No Employee Stock Options have been granted to the employees of the Company and thus no disclosure is required.

CREDIT RATINGS

During the year ended March 31,2025, ICRA has:

a) reaffirmed long-term - fund based - cash credit rating

of [ICRA]AA (pronounced ICRA Double A) for ' 32.50

Crores and short-term - non-fund based rating of

[ICRA]A1+ (pronounced ICRA A One Plus) for ' 30

Crores bank facilities; and

b) assigned long term - fund based - term loan credit rating of [ICRA]AA (pronounced ICRA Double A) for ' 100.0 Crores, to the Company.

CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES

All contracts/arrangements/transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis and approved by the Audit Committee.

During the year, the Company has not entered into any contract / arrangement / transaction with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions. Since, there were no material transactions of the Company with any of its related parties, disclosure of the Related Party Transactions as required under Section 134(3)

(h) of the Companies Act, 2013, in AOC-2 is not applicable to the Company.

The details of RPTs during the financial year, including transactions with person or entities belonging to the promoter/ promoter group which hold(s) 10% or more shareholding in the Company are provided in the accompanying financial statements.

The policy on materiality of related party transactions as approved by the Board may be accessed on the Company's Policy-on-Related-Party-Transaction.pdf .

Your Directors draw the attention of the members to Notes to the financial statements which sets out related party disclosures.

During the financial year, the Independent Directors of the Company had no pecuniary relationship or transactions with the Company other than sitting fees, commission and reimbursement of expenses, as applicable.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

Disclosure pertaining to remuneration and other details as required under Section 197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to the Report as Annexure -1.

Statement containing particulars of top 10 employees and particulars of employees as required under Section 197 (12) of the Act read with Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided as a separate Annexure forming part of this report.

In terms of proviso to Section 136(1) of the Act, the Report and Accounts are being sent to the Shareholders, excluding the aforesaid Annexure. The said Statement is also open for inspection. Any member interested in obtaining a copy of the same may write to the Company Secretary.

No Employee Stock Options have been granted to the employees of the Company and thus no disclosure is required.

INDUSTRIAL RELATIONS

The Industrial Relations continued to be cordial during the year under review.

CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

As part of its initiatives under Corporate Social Responsibility (CSR), the Company has undertaken projects in the areas of Community Development, Healthcare, Education & Skill Development and Research in Healthcare.

These projects are in accordance with Schedule VII of the Companies Act, 2013. The Report on CSR activities for the financial year 2024-25 is annexed herewith marked as Annexure - 2 to this Report.

STATUTORY AUDITORS

The Members at the Annual General Meeting held on September 23, 2022, had approved the re-appointment of Statutory Auditors of your Company namely, M/s S.N. Dhawan & Co., LLP, Chartered Accountants, for the second and final term of five consecutive years, to hold office from the conclusion of the 34th Annual General Meeting till the conclusion of the 39th Annual General Meeting to be held in the year 2027.

The Report given by Statutory Auditors on the financial statement of the Company for the financial year 2024-25 forms part of the Annual Report. The Notes on the financial statements referred to in the Auditors' Report are selfexplanatory and do not call for any further comments.

The Auditors' Report on the financial statements of the Company for the financial year ended March 31, 2025,

is unmodified i.e. it does not contain any qualification, reservation or adverse remark.

COST AUDITORS

Pursuant to Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Amendment Rules, 2014, the Directors on the recommendation of the Audit Committee, appointed M/s Devarajan Swaminathan and Co., Cost Accountants (FRN 100669), to audit the cost accounts of the Company for the financial year 2025-26 on a remuneration of ' 6.50 Lacs.

As required under the Companies Act, 2013, the remuneration payable to the Cost Auditor is required to be placed before the members in a general meeting for their ratification. Accordingly, a resolution seeking member's ratification for the remuneration payable to M/s Devarajan Swaminathan and Co., Cost Accountants (FRN 100669), is included at Item No. 7 of the Notice convening the Annual General Meeting.

The Company has maintained cost records in accordance with the provisions of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Amendment Rules, 2014, in respect of healthcare services.

SECRETARIAL AUDITORS

The Board of Directors of the Company based on the recommendation of Audit Committee, propose to appoint M/s RSM & Co., Peer Reviewed Firm of Practicing Company Secretaries, (Firm Registration No. P1997DE017000), as the Secretarial Auditors of the Company, to undertake secretarial audit of the Company for a period of five consecutive years commencing from Financial Year 202526 to FY 2029-2030.

The Company has received a written consent, eligibility letter and other necessary declarations and confirmations from M/s RSM & Co., Practicing Company Secretaries, stating that they satisfy the criteria provided under Section 204 of the Companies Act, 2013 read with Regulation 24A of Listing Regulations and that the appointment, if made, shall be in accordance with the applicable provisions of the Act and rules framed thereunder.

If approved by the Members, the appointment of M/s RSM & Co., Practicing Company Secretaries as the Secretarial Auditors will be for a period of five consecutive years commencing from Financial Year 2025-26 to FY 2029-2030.

Secretarial Auditors Report

Pursuant to the provisions of Section 204 of the Companies Act, 2013, and Regulation 24A of the Listing Regulations, the Board had appointed M/s RSM & Co., a firm of Company Secretaries in Practice, to conduct Secretarial Audit for the financial year ended March 31,2025. The Secretarial Audit Report for the financial year ended March 31, 2025, is annexed herewith marked as Annexure - 3, to this Report. During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards etc. and the same is covered under the Secretarial Audit Report, save and except that the Govt. of NCT of Delhi - one of the promoters of the Company, have not dematerialised their shareholding in the Company. Requests have been made by the Company to the GNCTD to get their shareholding dematerialised.

Internal Auditors

The Board of Directors of the Company based on the recommendations of the Audit Committee, appointed M/s SCV & Co. LLP., as Internal Auditors to conduct Internal Audit of the Company for a period up to September 30, 2027.

Board's response on Auditor's qualification, reservation or adverse remarks or disclaimer made.

The Directors hereby confirm that there are no qualifications, reservations or adverse remark made by the statutory auditors of the Company or in the secretarial audit report by the practicing company secretary and secretarial compliance report for the year ended March 31,2025.

REPORTING OF FRAUDS BY AUDITORS

During the year under review, neither the statutory auditors nor the secretarial auditors has reported to the Audit Committee, under Section 143 (12) of the Companies Act, 2013, any instances of fraud committed against the Company by its officers or employees.

OTHER DISCLOSURES:

a) During the year, the Company had complied with the applicable, Secretarial Standards relating to "Meetings of the Board of Directors" and "General Meetings" during the year.

b) There are no proceedings initiated/pending against the Company under the Insolvency and Bankruptcy Code, 2016, which materially impact the business of the Company.

c) There were no instances where the Company required the valuation for one time settlement or while taking loans from the Banks or Financial Institutions.

PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO.

Information as required to be disclosed on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013, read with Rule 8 of the Companies (Accounts) Rules, 201 4, is annexed herewith marked as Annexure - 4 to this Report.

ANNUAL RETURN

In accordance with the provisions of Section 92(3) read with section 1 34(3)(a) of the Companies Act, 201 3, and Rules framed thereunder, an annual return in the prescribed format for the financial year 2024-25 is available on the website of delhi/investor-relations/ .

ACKNOWLEDGEMENT

Your Directors wish to place on record their appreciation of the contribution made by the consultant doctors and the employees at all levels, towards the continued growth and prosperity of your Company.

Your Directors also wish to place on record their appreciation of business constituents, bankers and other financial institutions, the Government of NCT of Delhi and shareholders of the Company for their continued support.

For and on behalf of the Board of Directors

Dr. Prathap C. Reddy

Vice Chairman (DIN 00003654)

Place : New Delhi Date : August 6, 2025

Annexure 2 to Directors' Report

Annexure 2 to Directors' Report (Contd.)